share_log

Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30

Benzinga ·  May 8 10:20

Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $31 to $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment